Our lead product candidate, BDC-1001, is our HER2 Boltbody ISAC that seeks to improve therapeutic outcomes for patients with HER2-expressing tumors:
- HER2-positive breast and gastric cancer refractory to existing anti-HER2 therapies,
- Tumors with lower expression of HER2 that are not eligible for approved therapies, and
- Other HER2-positive tumors not eligible for approved therapies.
In addition, our innovative BDC-1001 approach seeks to address this critically important unmet medical need not only in patients with advanced tumors, but also in adjuvant settings.
BDC-1001 is currently in clinical development for the treatment of patients with HER2-expressing solid tumors, including subsets with HER2-low tumors. BDC-1001 is an ISAC; it is comprised of a HER2-targeting biosimilar trastuzumab which is conjugated to one of our proprietary TLR7/8 agonists, and is designed to maximize the potential anti-tumoral response of the immune system.